الدكتور محمد فرحان
أستاذ مشارك
الدكتور محمد فرحان
أستاذ مشارك
المؤهلات العلمية
PhD in Biotechnology
MSc in Biotechnology
الكيان
كلية العلوم الصحية والحيوية
السيرة الذاتية
Dr. Mohammad Farhan is an Associate Professor at the College of Health and Life Sciences at Hamad Bin Khalifa University. He leads an innovative research program focused on the genomics and epigenetics of psychiatric and neurological disorders. With a PhD in transcriptomic biomarkers of acquired epilepsy from the Institute of Genomics & Integrative Biology, Delhi, and postdoctoral training at the University of Oxford and A-STAR & Duke-NUS Medical School, he has cultivated a multidisciplinary expertise. At Hamad Bin Khalifa University, Dr. Farhan has established active collaborations with Sidra Medicine and Hamad Medical Corporation, investigating the genetics and biomarkers of mental health disorders in the Qatari population.
Dr. Farhan is a member of several scientific societies and serves as an editor for Translational Medicine Communications and Frontiers in Molecular Neuroscience. His research endeavors are supported by various grants from QNRF, MRC, and HBKU. Dr. Farhan’s research aims to unravel the molecular underpinnings of these conditions and pave the way for precision medicine approaches. Dr. Farhan's contributions to the field have been recognized through publications in high-impact journals such as Nature Methods, Neuron, Current Biology, PLOS Biology, BMC Medicine, etc. He actively engages in scientific outreach, participating in op-eds for newspapers, magazines, and TV shows, both locally and internationally.
PhD in Biotechnology
Savitribai Phule Pune University, India
2009
MSc in Biotechnology
Jamia Hamdard, India
2003
BSc (Hons.)
Aligarh Muslim University, India
2001
- Deciphering the genetic and epigenetic basis of Cerebral Palsy in Qatar for precision medicine strategies.
- Establishing a comprehensive precision medicine pipeline for Autism Spectrum Disorder, spanning variant validation to multi-level phenotyping.
- Pioneering precision psychiatry through peripheral biomarker exploration and targeted therapeutics for Schizophrenia and treatment resistance.
- Leveraging Drosophila models, in-silico approaches, and machine learning to advance therapeutic discovery for neurological and psychiatric disorders.
Associate Professor
College of Health & Life Sciences, Hamad Bin Khalifa University
2024 - Present
Assistant Professor
College of Health & Life Sciences, Hamad Bin Khalifa University
2018 - 2024
Postdoctoral & Senior Research Fellow
Neuroscience and Behavioural Disorders, Duke-NUS Medical School, Singapore
2011 - 2018
Postdoctoral Fellow
Institute of Molecular & Cell Biology, The University of Oxford, United Kingdom
2009 - 2010
Complete Publication Listing(s): Google Scholar
- QNRF-NPRP14S: (LPI); A Precision Medicine Initiative To Target Pediatric Cerebral Palsy, A Movement Disorder. (US$ 629,557).
- QNRF-UREP28 (LPI): Exploring neuronal and non-neuronal defects associated with neurodevelopmental disorders. (US$ 10,000)
- QNRF- NPRP13S: (PI); Establishing a precision medicine platform to target colorectal cancer in preclinical models. (US$ 420,000).
- HMC-MRC-2022: (PI); Mechanisms mediating resistance to antipsychotic therapy in schizophrenia: Identifying novel therapeutic targets in the Qatari population. (US$ 100,000).
- HMC-MRC-2023: Role of Inflammatory Biomarkers in the Treatment Efficacy in Patients with Major Depressive Disorder. (US$ 100,000).